 | Up a level |
2021
Bishop, Michael R., Dickinson, Michael, Purtill, Duncan, Barba, Pere, Santoro, Armando, Hamad, Nada, Kato, Koji, Sureda, Anna, Greil, Richard, Thieblemont, Catherine, Morschhauser, Franck, Janz, Martin, Flinn, Ian W., Rabitsch, Werner, Kwong, Yok Lam, Kersten, Marie Jose, Minnema, Monique C., Holte, Harald, Chan, Esther Hian Li, Martinez-Lopez, Joaquin, Mueller, Antonia M. S., Maziarz, Richard T., McGuirk, Joseph P., Bachy, Emmanuel, Le Gouill, Steven, Dreyling, Martin, Harigae, Hideo, Bond, David A., Andreadis, Charalambos, McSweeney, Peter A., Kharfan-Dabaja, Mohamed A., Newsome, Simon, Degtyarev, Evgeny, Del Corral, Chris, Andreola, Giovanna, Masood, Aisha, Schuster, Stephen J., Jaeger, Ulrich, Borchmann, Peter and Westin, Jason R. (2021). Tisagenlecleucel Vs Standard of Care As Second-Line Therapy of Primary Refractory or Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma: Analysis of the Phase III Belinda Study. Blood, 138. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020